Journal
CANCER
Volume 120, Issue 20, Pages 3122-3130Publisher
WILEY
DOI: 10.1002/cncr.28850
Keywords
hepatocellular carcinoma; targeted therapy; sorafenib; angiogenic; doxorubicin; cabozantinib; tivantinib; everolimus; pegylated arginine deiminase (ADI-PEG 20); tremelimumab
Categories
Funding
- Abbott Laboratories
- Amgen
- Bayer
- Eli Lilly and Company/Imclone
- Exelixis
- Genentech
- Momenta Pharmaceuticals
- Myriad Genetics
- Novartis
- OncoMed Pharmaceuticals
- Polaris Pharmaceuticals
- Roche
- Sanofi-Aventis
- Vicus Therapeutics
- Aduro Biotech
- Astellas Pharma US
- AstraZeneca
- Celgene
- Celsion
- Cipla
- Eli Lilly and Company
- IntegraGen
- Jennerex Biotherapeutics
- MedImmune
- Pharmacyclics
- Silenseed
Ask authors/readers for more resources
Hepatocellular carcinoma is a common malignancy with a poor prognosis. Sorafenib is the only systemic therapy known to improve the overall survival of patients with advanced disease. The clinical benefit of sorafenib is modest and the mechanistic basis for its activity is unknown. Four phase 3 clinical trials have failed to improve on sorafenib in the frontline setting and no agent has been shown to impact outcomes after sorafenib failure. Several factors have contributed to this recent stall in drug development but new approaches hold promise and currently are being investigated. This review will focus on the current pipeline of experimental therapeutics for patients with advanced hepatocellular carcinoma and shed a light on scientific limitations that hamper the advancement of new therapies for this disease, and ways around it. (C) 2014 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available